Thursday’s biggest gaining and declining stocks

NEW YORK (MarketWatch) � Shares of the following companies were among those that made notable moves in Thursday�s Wall Street session:

Gainers

Bed Bath & Beyond BBBY �shares rose 8.5%. Late Wednesday, the company said its fourth-quarter profit jumped 32% to $1.48 a share on revenue of $2.73 billion. Both results came in well ahead of consensus estimates in a FactSet Research survey of analysts.

Click to Play Google wants to change our view of the world

Google announced an augmented reality project where glasses are used as a pop-up display on which common smartphone applications are run. WSJ's Neil McIntosh discusses whether Google really will give us a different view of the world.

Shares of PPG Industries PPG �rose 2.5% after the company said new cost cuts will eliminate about 2,000 positions, but first-quarter profit will beat Wall Street targets after breaking out one-time costs. PPG said it�ll report adjusted first-quarter profit of $1.75 a share to $1.80 a share. Wall Street analysts had expected the coatings maker to earn $1.44 a share.

TJX Cos. TJX �rose 2.4% after reporting that its March same-store sales rose 10%, topping Wall Street expectations. The retailer also upped its fiscal first quarter profit target to 51 cents to 52 cents, ahead of a previous view 45 cents to 47 cents.

Decliners

Shares of Constellation Brands STZ �fell 12%. The wine and spirits maker posted strong earnings for the fourth quarter of fiscal 2012, but it cautioned that profit will drop for fiscal 2013.

Shares of PolyCom Inc. PLCM �shares shed 20%. The company said it expects first-quarter revenue of $364 million to $370 million, with earnings pegged at 7 cents to 9 cents a share, down from 19 cents earned in the year-ago period. Analysts polled by FactSet had expected the company to earn 30 cents a share on revenue of $399.5 million.

Spectrum Pharmaceuticals Inc. SPPI �shares fell 9.4% as the company agreed to buy Allos Therapeutics Inc. ALTH �in a deal worth up to $206 million. Spectrum also disclosed that anticancer drug apziquone failed to meet expectations in Phase III clinical trials.